Literature DB >> 24604059

Targeted therapy in pediatric low-grade glioma.

John-Paul Kilday1, Ute Katharina Bartels, Eric Bouffet.   

Abstract

Collectively, pediatric low-grade gliomas account for most brain tumors reported in children. Surgery is typically curable for operable lesions. However, more effective therapies are required for inaccessible tumors, both to overcome refractory disease and to minimize the toxicity associated with conventional adjuvant chemotherapy and radiotherapy regimens. Recent years have witnessed rapid improvements in our understanding of the molecular pathogenesis of several childhood tumors, including low-grade gliomas. As a result, several novel compounds targeting and inhibiting critical components of molecular signaling pathways purported to be overactive in the disease have been developed. This article summarizes the most recent literature evaluating such novel targeted agents in childhood low-grade gliomas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24604059     DOI: 10.1007/s11910-014-0441-0

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  66 in total

1.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.

Authors:  T N Basu; D H Gutmann; J A Fletcher; T W Glover; F S Collins; J Downward
Journal:  Nature       Date:  1992-04-23       Impact factor: 49.962

2.  Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.

Authors:  Eric Bouffet; Regina Jakacki; Stewart Goldman; Darren Hargrave; Cynthia Hawkins; Manohar Shroff; Juliette Hukin; Ute Bartels; Nicholas Foreman; Stewart Kellie; Joanne Hilden; Michael Etzl; Beverly Wilson; Derek Stephens; Uri Tabori; Sylvain Baruchel
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

Review 3.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

Review 4.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

5.  Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.

Authors:  W G Janzarik; C P Kratz; N T Loges; H Olbrich; C Klein; T Schäfer; W Scheurlen; W Roggendorf; C Weiller; C Niemeyer; R Korinthenberg; S Pfister; H Omran
Journal:  Neuropediatrics       Date:  2007-04       Impact factor: 1.947

Review 6.  Brain tumors across the age spectrum: biology, therapy, and late effects.

Authors:  Thomas E Merchant; Ian F Pollack; Jay S Loeffler
Journal:  Semin Radiat Oncol       Date:  2010-01       Impact factor: 5.934

7.  Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.

Authors:  Angela J Sievert; Shih-Shan Lang; Katie L Boucher; Peter J Madsen; Erin Slaunwhite; Namrata Choudhari; Meghan Kellet; Phillip B Storm; Adam C Resnick
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

8.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

Authors:  David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister
Journal:  Nat Genet       Date:  2013-06-30       Impact factor: 38.330

Review 9.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.

Authors:  Jingxiang Huang; Brendan D Manning
Journal:  Biochem J       Date:  2008-06-01       Impact factor: 3.857

Review 10.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09
View more
  8 in total

Review 1.  Pediatric cerebellar astrocytoma: a review.

Authors:  Christopher M Bonfield; Paul Steinbok
Journal:  Childs Nerv Syst       Date:  2015-09-09       Impact factor: 1.475

Review 2.  An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update.

Authors:  Alvaro Lassaletta; Michal Zapotocky; Eric Bouffet; Cynthia Hawkins; Uri Tabori
Journal:  Childs Nerv Syst       Date:  2016-09-20       Impact factor: 1.475

Review 3.  Improving Care in Pediatric Neuro-oncology Patients: An Overview of the Unique Needs of Children With Brain Tumors.

Authors:  Cheryl Fischer; Mary Petriccione; Maria Donzelli; Elaine Pottenger
Journal:  J Child Neurol       Date:  2015-08-05       Impact factor: 1.987

Review 4.  Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma.

Authors:  Tabitha Cooney; Kee Kiat Yeo; Cassie Kline; Michael Prados; Daphne Haas-Kogan; Susan Chi; Sabine Mueller
Journal:  Neurooncol Pract       Date:  2019-08-13

5.  CircFAM53B promotes the proliferation and metastasis of glioma through activating the c-MET/PI3K/AKT pathway via sponging miR-532-3p.

Authors:  Jiaping Pei; Hui Dou; Xiaozhao Deng
Journal:  Cell Cycle       Date:  2022-01-31       Impact factor: 4.534

Review 6.  The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors.

Authors:  Hazel A Rogers; Jasper Estranero; Keshni Gudka; Richard G Grundy
Journal:  Oncotarget       Date:  2017-01-10

7.  Childhood brain tumors: It is the child's brain that really matters.

Authors:  David A Walker
Journal:  Front Oncol       Date:  2022-10-04       Impact factor: 5.738

Review 8.  Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors.

Authors:  Andrea Cimini; Maria Ricci; Agostino Chiaravalloti; Luca Filippi; Orazio Schillaci
Journal:  Int J Mol Sci       Date:  2020-05-28       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.